Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis

RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

More News: Acetaminophen | Allergy & Immunology | Amyloidosis | Anaphylactic Shock | Anemia | Atrial Fibrillation | Back Pain | Biotechnology | Blood Transusion | Brain | Bronchitis | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Child Development | Children | Chronic Obstructive Pulmonary | Chronic Pain | Clinical Trials | Constipation | Corticosteroid Therapy | Cough | Databases & Libraries | Dexamethasone | Emergency Medicine | Epidemiology | Hay Fever | Health Management | Heart | Heart Transplant | Hematology | Hypertension | Infectious Diseases | Influenza | Influenza Vaccine | Insomnia | Internet | Kidney Transplant | Kidney Transplantation | Laboratory Medicine | Laryngeal Cancer | Learning | Legislation | Liver | Liver Transplant | Lortab | Lymphoma | Myeloma | Neurology | Neuroscience | Oral Cancer | Pain | Pain Management | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Politics | Prednisone | Pregnancy | Pulmonary Hypertension | Rare Diseases | Respiratory Medicine | Revlimid | Science | Study | Thrombocytopenia | Toxicology | Transplant Surgery | Transplants | Universities & Medical Training | Urology & Nephrology | Vaccines | Velcade | Warnings | Women